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Abstract: Among the various mechanisms involved in aging, it was proposed long ago that a prominent
role is played by oxidative stress. A major way by which the latter can provoke structural damage
to biological macromolecules, such as DNA, lipids, and proteins, is by fueling the peroxidation of
membrane lipids, leading to the production of several reactive aldehydes. Lipid peroxidation-derived
aldehydes can not only modify biological macromolecules, by forming covalent electrophilic addition
products with them, but also act as second messengers of oxidative stress, having relatively
extended lifespans. Their effects might be further enhanced with aging, as their concentrations
in cells and biological fluids increase with age. Since the involvement and the role of lipid
peroxidation-derived aldehydes, particularly of 4-hydroxynonenal (HNE), in neurodegenerations,
inflammation, and cancer, has been discussed in several excellent recent reviews, in the present
one we focus on the involvement of reactive aldehydes in other age-related disorders: osteopenia,
sarcopenia, immunosenescence and myelodysplastic syndromes. In these aging-related disorders,
characterized by increases of oxidative stress, both HNE and malondialdehyde (MDA) play important
pathogenic roles. These aldehydes, and HNE in particular, can form adducts with circulating or
cellular proteins of critical functional importance, such as the proteins involved in apoptosis in
muscle cells, thus leading to their functional decay and acceleration of their molecular turnover and
functionality. We suggest that a major fraction of the toxic effects observed in age-related disorders
could depend on the formation of aldehyde-protein adducts. New redox proteomic approaches,
pinpointing the modifications of distinct cell proteins by the aldehydes generated in the course of
oxidative stress, should be extended to these age-associated disorders, to pave the way to targeted
therapeutic strategies, aiming to alleviate the burden of morbidity and mortality associated with
these disturbances.
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1. Introduction
In recent years, increased life expectancy due to an improved quality of life and decline in mortality
rates, is leading to a society in which the aging population is growing more rapidly than the entire
population. Life expectancy is projected to increase in industrialized countries. In 2016, 27.3 million
very old adults were living in the European Union, and in the UK, 2.4% of the population (1.6 million)
were aged 85 and over [1]. It has been calculated that there is more than a 50% probability that,
by 2030, female life expectancy will exceed the 90-year barrier, a level that was deemed unattainable
at the turn of the 21st century [2]. The functional disturbances appearing in old age are referred to
as the “aging process”, which entails changes in body composition, imbalances in energy production
and use, homeostatic dysregulation, neurodegeneration and loss of neuroplasticity [3]. The scientific
community has formulated over 300 theories to explain the driving forces behind aging [4], but none
has proven, so far, to be universally applicable. The free radical theory of aging has gained widespread
acceptance, thus becoming one of the leading explanations of the aging process at the molecular level.
It is commonly believed that the aging process is related to an imbalance favoring pro-oxidant over
antioxidant molecules and a consequent increase of oxidative stress [5]. Oxidative stress entails elevated
intracellular levels of reactive oxygen species (ROS), which can cause damage to proteins, lipids,
and DNA. The mitochondria are the primary sources of intracellular ROS (~1–5%), due to the electron
leakage primarily resulting from the electron transport chain [6]. Indeed, mitochondrial dysfunction
has long been considered a major contributor to aging and age-related diseases. In elderly subjects,
mitochondria are characterized by functional impairment, such as lowered oxidative capacity, reduced
oxidative phosphorylation, decreased adenosine triphosphate production, significantly increased ROS
generation, and diminished antioxidant defense [7]. Depending on their concentration in the cells,
ROS are either physiological signals essential for cell life or toxic species which damage cell structure
and functions. In particular, ROS cause the oxidation of polyunsaturated fatty acids in membrane
lipid bilayers, leading eventually to the formation of aldehydes, which have been considered as toxic
messengers of oxidative stress, able to propagate and amplify oxidative injury [8].
Among the aldehydes produced by lipid peroxidation (LPO), malonaldehyde (MDA) and
4-hydroxynonenal (HNE) have gained most attention, since MDA is produced at high levels during
LPO, so that it is commonly used as a measure of oxidative stress, and HNE has been shown to be
endowed with the highest biological activity. The production, metabolism, and signaling mechanisms
of two main omega-6 fatty acids lipid peroxidation products, MDA and HNE, have been extensively
studied and reported in an excellent review [9]. Briefly, MDA and HNE originate from the peroxidation
of polyunsaturated fatty acids. LPO can be described generally as a process under which oxidant,
free radical or non-radical chemical species attack lipids containing carbon–carbon double bond(s).
This process involves hydrogen abstraction from a carbon atom and oxygen insertion, resulting in the
formation of peroxyl radicals and lipid hydroperoxides, as illustrated in Figure 1.
Since aldehydes have high chemical reactivities, mammals have evolved a full set of enzymes
converting them into less reactive chemical species and contributing to the control of their intracellular
concentrations, which reflect the steady-state between the rates of formation by LPO and catabolism
into less reactive compounds. Once formed, MDA and HNE can be reduced to alcohols by aldo-keto
reductases or alcohol dehydrogenases, or can be oxidized to acids by aldehyde dehydrogenases [10].
Moreover, HNE, which is the most reactive among aldehydes, easily reacts with low-molecular-weight
compounds, such as glutathione. This reaction can occur spontaneously or can be catalyzed by
glutathione-S-transferases [10]. HNE and MDA are able to affect several signaling processes. Most of
these effects depend on their ability to bind covalently to proteins and DNA.
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Figure 1. Malondialdehyde (MDA) and 4-hydroxynonenal (HNE) formation from polyunsaturated
fatty acids.
Aldehyde–Protein Adduct in Human Disease
LPO-derived aldehydes easily react with proteins, generating a wide variety of intra- and
inter-molecular covalent adducts. Depending on their structural features, they can form Schiff bases
and/or Michael adducts with the free amine group of lysine, the imidazoline group of histidine,
the guanidine group of arginine and the thiol group of cysteine [11]. HNE can affect cell functions,
through its ability to form adducts with proteins involved in signal transduction and gene expression,
including receptors, kinases, phosphatases and transcription factors [11]. MDA can form protein
adducts by specifically modifying the lysyl residues of proteins [12], and modified autologous
biomolecules can generate neoepitopes from self epitopes, capable of inducing undesired innate and
adaptive immune responses, including atherosclerosis [13]. HNE adducts can accumulate progressively
in the vascular system, leading to cellular dysfunctions and tissue damaging effects, which are involved
in the progression of atherosclerosis. Moreover, HNE, by forming HNE-apoB adducts, contributes
to the atherogenicity of oxidized low-density lipoproteins (LDL), leading to the formation of foam
cells [14]. The presence of HNE-protein adducts has been detected in inflammation-related diseases,
such as alcoholic liver disorders and chronic alcoholic pancreatitis, in which the increased formation of
HNE-protein adducts was evidenced in acinar cells adjacent to the interlobular connective tissue [15].
Moreover, HNE-protein adducts have been detected in brain tissues and body fluids in several
neurodegenerative diseases, such as Alzheimer’s disease, Huntington disease, Parkinson’s disease,
amyotrophic lateral sclerosis, and Down syndrome [10].
The involvement of MDA and HNE in age-related diseases has been supported by the observations
that the concentrations of MDA and HNE, in human erythrocytes and blood plasma, increased
during the aging process [16]. The role of reactive aldehydes in age-related pathologies, such as
atherosclerosis [13], neurodegenerations [17], inflammation, and cancer [10] has been discussed by
many excellent reviews. Other age-related disorders, such as osteopenia/osteoporosis, sarcopenia,
immunosenescence and myelodysplastic syndromes have received less attention. In this review,
we focus our attention on to recent advances in the role of LPO-derived aldehydes and aldehyde-protein
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adducts in these age-related disorders, all of which are characterized by increases of oxidative stress
and consequent increases in the generation of LPO-derived aldehydes.
2. Osteopenia/Osteoporosis
Bone remodeling is a highly dynamic physiological process: osteoblasts (bone-forming cells) and
osteoclasts (bone-resorbing cells) work simultaneously to maintain bone density and strength [18].
During aging, bone density decreases and the measure of bone mineral density is commonly employed
to evaluate whether or not a patient is affected by osteopenia or osteoporosis. Osteopenia is the
thinning of bone mass. Such a decrease in bone mass is not usually “severe”, but is considered a very
serious risk factor for the development of osteoporosis. Osteoporosis is characterized by profound
losses of skeletal mass, coupled with architectural deterioration, which increase bone fragility and
susceptibility to fractures. Several recent papers have provided insights into the current prevalence of
osteoporosis in specific older populations. The current National Osteoporosis Foundation guidelines
for the USA, coupled with the most recently available population data from the National Health and
Nutrition Survey, show that the eligibility for osteoporosis treatment increases exponentially with
age; roughly 10% of both men and women meet criteria for treatment at age 50 years, whereas 48%
of men and 79% of women over 80 years meet treatment guidelines [19]. Current treatments for
osteoporosis, which increase bone density and reduce fracture risk, include anti-resorptive medications
(bisphosphonates and denosumab), which primarily increase endocortical bone and cortical thickness,
and anabolic medications (teriparatide and abaloparatide), which increase the periosteal and endosteal
perimeters, without causing large changes in cortical thickness [20].
Increases of ROS levels have been observed consistently in osteopenia and osteoporosis. In aging
people, the number and activity of individual osteoblasts decrease and osteoblast apoptosis increases,
in association with oxidative stress-induced osteoporosis [21]. Some studies explored the relationships
between the use of antioxidants and bone metabolism. Indeed, a marked decrease in plasma
antioxidants was found in aged or osteoporotic rats and in aged or osteoporotic women [22–24].
The loss of antioxidant capacity leads to accelerated bone loss through the activation of a tumor necrosis
factor alpha (TNF-α)-dependent signalling pathway [25]. In turn, the administration of antioxidants
such as vitamin C, E, N-acetyl-cysteine and linoleic acid, had beneficial effects in individuals with
osteoporosis [26].
Osteoblast apoptosis was induced by oxidative stress through the activation of the c-Jun
N-terminal kinase (JNK) pathway [27] and the NF-kB pathway [28]. In unstimulated cells, NF-κB
proteins are sequestered in the cytoplasm because of their association with IκB (inhibitor of κ light gene
enhancer in B cells) proteins. Phosphorylation and degradation of IκB disrupt this association and allow
the translocation of NF-κB proteins into the nucleus. ROS induce the oxidation of critical cysteines
and enhance the activity of several cytoplasmic kinases, which promote IκB phosphorylation and
degradation, including IκB kinase and the PKC family of serine/threonine kinases [29]. Additionally,
ROS-induced modifications control key steps in the nuclear phase of the NF-κB program, including
recruitment of coactivators, chromatin remodeling, and DNA binding. The activation of NF-kB in
osteoblastic cells increased the phosphorylation of p66 (shc) protein, which amplified mitochondrial
ROS generation and stimulated apoptosis [29]. The increase of ROS in osteoblastic MC3T3-E1 cells
induced phosphorylation of MAPKs (mitogen-activated protein kinases), which subsequently triggered
the intrinsic apoptosis pathway. Moreover, the advanced oxidation protein products induced osteoblast
apoptosis in aged Sprague–Dawley rats [30].
The NF-κB pathway is involved in osteoclast activity, as well. Indeed, ROS stimulated osteoclast
differentiation and activity through activation of the NF-κB pathway, and these effects were reversed
upon NF-κB suppression [31].
Other than by the direct actions mentioned above, ROS can affect bone turnover by enhancing the
production of LPO-derived reactive intermediates, thereby causing protein damage and inflammatory
responses [32]. In vitro experiments have proved that HNE, the most biologically active aldehyde
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produced by LPO, can induce intense oxidative stress, inflammatory reactions, and apoptosis in
osteoblasts, via the induction of protein phosphatase 2A activity, which has earned a reputation as a
mediator of oxidative stress-induced apoptosis in these cells [21]. The role of LPO-derived aldehydes
in osteoblast apoptosis is also supported by studies on aldehyde dehydrogenases (ALDH), a family
of enzymes involved in aldehyde degradation [33]. ALDH inhibition by disulfiram resulted in bone
loss in rats [34]. Additional confirmation of the role of ALDH activity in osteoporosis comes from the
results obtained with transgenic mice expressing the Aldh2*2 (Aldh2*2 Tg) dominant-negative form
of ALDH2. These transgenic mice exhibited severe osteoporosis, indicating that ALDH2 regulates
physiological bone homeostasis. Moreover, the Aldh2*2 transgene or treatment with acetaldehyde
induced the accumulation of HNE and the expression of peroxysome proliferator-activated receptor
γ (PPAR-γ) a transcription factor that promotes adipogenesis and inhibits osteoblastogenesis [35].
On the contrary, the activation of ALDH2 by N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide
(alda-1) had an osteogenic effect, involving increased production of bone morphogenetic protein-2 by
osteoblasts [36]. Taken together, these experimental data seem to delineate a role for the products of
LPO in the induction of osteoporosis. However, the measurements of MDA as an indicator of LPO
in post-menopausal osteoporotic women gave conflicting results. One study disclosed significant
increases in plasma MDA concentrations in post-menopausal osteoporotic women, compared with
control subjects [37], whereas another one failed to detect changes of MDA concentrations between
osteoporotic and non-osteoporotic post-menopausal women [38]. Thus, further studies are needed
to precisely define the role played by LPO-derived aldehydes and to validate the possible inclusion
of targeted therapies aimed to reducing the effects of reactive aldehydes in the development and
progression of age-related osteopenia/osteoporosis.
3. Sarcopenia
Sarcopenia is a geriatric syndrome characterized by a progressive and generalized loss of skeletal
muscle mass, together with low muscle strength and/or poor physical performance in the elderly [39].
A recent study in Brazilians aged 60 years or older demonstrated that the overall prevalence of
sarcopenia in older Brazilians was 17.0%. Sensitivity analysis showed rates of 20.0% in women and
12.0% in men [40]. In order to counteract the age-related muscle decline several interventions have been
explored, including protein supplementation, testosterone replacement in men, estrogen replacement
in women, growth hormone replacement, and treatment with vitamin D. To date, adequate protein
intake and physical exercise are the most promising interventions aiming to prevent and/or delay the
decline of muscle mass [41].
Oxidative stress and inflammation are implicated in the pathogenesis of sarcopenia [42]. It has
been suggested that an increase of oxidative stress might activate apoptosis, leading to the loss of
skeletal muscle fibers, thus contributing to the progression of sarcopenia [43]. Skeletal muscle tissue
is unique, with respect to apoptosis, because muscle cells are one of the three cell types, along with
osteoclasts and cytotrophoblasts, that are multinucleated [44]. The process by which nuclei are
eliminated from multinucleated muscle fibers appears to be similar to apoptosis, since it involves
chromatin condensation and DNA fragmentation. Moreover, it has been suggested that oxidative
stress and the consequent mitochondrial genotoxic damage might play a causal role in the numerical
loss of muscle fibers with aging [45].
Deregulation of redox homeostasis has emerged in recent years as a common pathogenetic
mechanism and potential therapeutic target in collagen VI-related congenital muscular dystrophies,
and in Duchenne muscular dystrophy, as well as in other more prevalent processes, such as age-related
muscle loss [46]. Moreover, sarcopenia can be associated with obesity. This association is defined as
sarcopenic obesity and represents a chronic condition, whose increase in prevalence has been related
to parallel increases in the mean age of the population, the prevalence of obesity, and the changes in
lifestyle during the last several decades [47]. In obese individuals, adipose tissue secretes both bioactive
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molecules, called “adipokines”, and ROS, which might represent the mechanistic link between obesity
and its associated metabolic complications, including sarcopenia [48].
The aging of human skeletal muscle cells is marked by a progressive functional decline of
mitochondria, resulting in the accumulation of ROS [43]. Sod1−/− mice lack the superoxide dismutase
[Cu-Zn] 1 (CuZnSOD1) enzyme and undergo accelerated sarcopenia, i.e., display the characteristics of
aging muscle in an accelerated manner. In Sod1−/− mice, muscle loss was accompanied by a progressive
decline of mitochondrial function, with an increased mitochondrial generation of ROS and faster
induction of mitochondrial-mediated apoptosis and loss of myonuclei. Sod1−/− mice also exhibited
a strikingly increased number of dysfunctional mitochondria near neuromuscular junctions [49].
Increased ROS production is a necessary response to exercise of a sufficient intensity [50]. ROS and RNS
(reactive nitrogen species, such as NO and the peroxynitrite anion) play important roles in the function
of skeletal muscle, as they may mediate muscle adaptive responses, e.g., to physical exercise [51],
by facilitating glucose uptake or inducing mitochondrial biogenesis [52,53]. However, during extended
disuse periods, redox imbalance contributes to deleterious muscle remodeling via myonuclear
apoptosis and atrophy, with the mediation of a redox-sensitive transcriptional regulator, NF-κB [54,55].
ROS can stimulate the production of TNF-α and IL-1β, through the activation of NF-κB-mediated
pathways [56]. Systemic inflammation, impaired responses to stressors, and weakened regenerative
capacity are all associated with sarcopenia. In Wistar rats, aging (40 weeks) was accompanied
by reduced mitochondrial respiratory chain complex activities in saponin-skinned soleus muscle
fibers, increased production of ROS and decreased transcription of the genes encoding mitochondrial
superoxide dismutase 2 (SOD2), PPAR-γ coactivator-1β (PGC-1β) and sirtuin 1, in comparison with
young (16 weeks) rats. Chronic intake of polyphenols normalized Vmax, decreased ROS production
and enhanced SOD2 and PGC-1β expression, in comparison with age-matched untreated rats [57].
Notably, sarcopenia is also accompanied by fat infiltration in the skeletal muscle, which can
not only affect muscle quality and functional performance [58], but might render muscle tissue
prone to oxidative stress-induced LPO. In disease processes marked by increased ROS production,
novel 2,4-dinitrophenylhydrazine (DNPH)-reactive carbonyl groups in proteins, susceptible to
spectrometric or antibody-mediated detection, might be either produced by the direct metal-catalyzed
oxidation of aminoacyl side chains or introduced by stable adduct formation via the reaction of
the latter with reducing sugars or reactive carbonyl species, including MDA and HNE. Age-related
increases in protein carbonyl levels were detected in skeletal muscle by derivatization with DNPH,
followed by fluorescent anti-DNPH antibodies, in descending ranking order, in the extracellular space,
subsarcolemmal mitochondria, intermyofibrillar mitochondria and cytoplasm [59]. By the use of
quantitative proteomics, a number of mitochondrial proteins susceptible to carbonylation in a muscle
type-dependent (slow- vs. fast-twitch) and age-dependent manner were identified in Fischer 344 rat
skeletal muscle. Fast-twitch muscle revealed twice as many carbonylated mitochondrial proteins than
slow-twitch muscle, with 22 proteins showing significant changes (mostly increases) in carbonylation
state with age. Ingenuity pathway analysis revealed that these proteins belonged to functional classes
and pathways known to be impaired in muscle aging, including cellular function and maintenance,
fatty acid metabolism and citric acid cycle. Although proof was not provided that carbonylation was
responsible for any functional changes, these data delineated a catalog of protein targets deserving
investigation, because of their potential implication in muscle aging [60]. In the gastrocnemius muscle
of male C57B1/6 mice, a distinct increase of HNE adducts was noticed, upon the progression of age
from 5 to 25 months. This was accompanied by increased expression of inducible nitric oxide synthase,
decreased expression of G6PDH, activation of JNK, caspase 2, caspase 9, and inactivation of BCL-2,
through phosphorylation at Ser70 [61]. Other observations have been collected in transgenic mice
expressing a dominant-negative form of ALDH2 (ALDH2*2 Tg mice), which indicate a role of HNE as
an inducer of apoptosis. Mice, in whose muscles ALDH activity was selectively attenuated, exhibited
small body size, muscle atrophy, decreased fat content, osteopenia, and kyphosis, accompanied by
increased muscular HNE levels [62].
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Oxidative stress, in sarcopenic patients, can lead to increased LPO production. The mechanistic
importance of apoptosis in the loss of muscle cells in age-related sarcopenia and the involvement of
LPO-derived aldehydes in this process are supported by several studies. The abundance of protein
carbonyl adducts was determined within skeletal muscle sarcoplasmic, myofibrillar, and mitochondrial
protein subfractions from musculus vastus lateralis biopsies, using immunoblotting techniques, in two
groups of 16 old males (“old” and “old sarcopenic”) [63]. Concentrations of cytoprotective proteins
(e.g., heat shock proteins, αβ-crystallin) were also assayed. Aging was associated with increased
mitochondrial (but not myofibrillar or sarcoplasmic) protein carbonyl adducts, independent of (stage-I)
sarcopenia. Mitochondrial protein carbonyl abundance negatively correlated with muscle strength, but
not muscle mass. According to this study, mitochondrial protein carbonylation increased moderately
with age, and this increase might impact upon skeletal muscle function, but was not a hallmark of
sarcopenia, per se. It should be considered, though, that the subjects under study were affected by
low-grade (stage-I) sarcopenia [63].
A recent study, conducted with an urban Spanish cohort of elderly people (≥70 years),
demonstrated a significant increase of MDA and HNE in blood samples of sarcopenic subjects,
with respect to sarcopenia-exempt control subjects [64]. Notably, among several parameters examined in
this study, only MDA and HNE levels were significantly associated with sarcopenia. These observations
have been confirmed by studies demonstrating the presence of plasma MDA/HNE protein adducts
in sarcopenic patients [65]. Interestingly, proteomic analysis of muscle extracts from adult and aged
post-menopausal women demonstrated that ALDH2 and AKR1A1 were up-regulated in aged women,
suggesting that the scavenging of reactive aldehyde products in skeletal muscle cells of the elderly was
enhanced [66]. These results may be interpreted as a demonstration of the existence of a mechanism of
adaptation of muscle cells to increased oxidative stress and to the consequently increased production
of LPO-derived aldehydes.
Taken together, these results support a pathogenic link between oxidative stress, LPO-derived
aldehydes, aldehyde-protein adducts and age-related sarcopenia in humans.
4. Immunosenescence
Immunosenescence takes a relevant part in the aging phenotype, and there is growing
consensus on the idea that it might result from a progressive imbalance, favoring inflammatory
over anti-inflammatory mechanisms, which some authors define as “inflammaging”. According
to this view, continuing antigenic stimulation in the course of life, with accompanying oxidative
stress, steadily leads, as enzymatic and non-enzymatic antioxidant defences fade off with age, to an
up-regulation of inflammatory responses and a remodeling of immune responses, as revealed by the
increased serum levels of pro-inflammatory cytokines, such as IL-6 and TNF-α, and a loss of efficacy of
adaptive responses. Pro-inflammatory cytokines stimulate further the generation of ROS and cytotoxic
LPO products.
As already well documented in other tissues and organ systems, accumulation of ROS and LPO
products might cause significant damage to cell lipids, nucleic acids and crucial cell proteins also in
cells of the immune system. This pro-inflammatory condition negatively affects the overall chances for
good health, self-sufficiency and extended survival of the elderly and is a hallmark of the so-called
“fragility” of the elderly [67,68]. Moreover, the remodeling of immunity strongly contributes to a
number of age-associated diseases (infectious diseases, autoimmunity, cancer, metabolic, vascular and
neurodegenerative diseases). Immunosenescence is best revealed by the changes in the modulation
of survival of T cells, which become more resistant to damage-induced apoptosis. As a consequence,
CD28-senescent T cells increase in number (with effector/memory cells, most of the CD8+ CD45RO+
CD25+ phenotype, prevailing over naïve cells), dysfunctional cells accumulate, and the immunological
space in lymphoid tissues is reduced. Increased activation-induced cell death (AICD), in response to
TNF-α, causes a progressive depletion of lymphoid niches, particularly of the naïve T cell compartment.
At the same time, the generation of immunocompetent T cells in thymus declines with age [68–72].
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The age-dependent shortening of DNA telomeres, which is associated with increased mortality in
individuals over 65 years of age, contributes to the reduction of the potential for clonal expansion and
differentiation of naïve T cells, which is revealed by the dramatic decay of T-cell-receptor excision
circles (TREC). The overall outcome is a reduction in the repertoire of clonal antigenic specificities,
which is reflected in a decreased ability to enact recall immune responses to formerly encountered
antigens (e.g., cytomegalovirus, CMV) and to mount adaptive responses to novel antigenic stimuli,
combined with an increased tendency to autoimmunity [68–72]. The inversion of the CD4+/CD8+ cell
number ratio, the increased fraction of effector-memory cells and the seropositivity for CMV identify
an immune risk phenotype in elderly patients [73]. Reduced B cell function with age reflects the
decreases both of CD19+ cell number and of T helper-mediated cooperation with B cell responses.
Age-associated changes in innate immunity include reductions of antigen uptake by DCs, phagocytosis
and production of lymphocyte-derived chemotactic factor by macrophages, FCγRIII (CD16)-stimulated
production of superoxide anion by neutrophils, and IFN-γ secretion and expression of activating NKp
receptors by NK cells.
Thymus involution is associated with a drastic reduction in organ volume and replacement of
functional cortical and medullary areas with adipose tissue. This process, which starts early in life,
is almost complete by the age of 40–50 years. Increasing formation of lipid-laden cells with aging
has also been observed in lympho-hematopoietic organs, including the thymus [74,75]. Age-related
thymic involution appears to reflect the compound effects of increased rates of thymocyte death in
the thymus and decreased thymic differentiation and output of T cells. The former might result
from intrathymic inflammation and lipotoxicity, the latter from the failure of stromal cell-dependent
thymocyte maturation and survival (Figure 2) [76].
Figure 2. Main aspects of thymic involution. The decrease of hematopoietic cells causes a decrease of
production of T cells from the thymus. HSC: hematopoietic stem cells; LIF: leukemia- inhibitory factor;
OSM: Oncostatin M; SCF: stem cell factor; IL-2: interleukin 2; IL-6 interleukin 6; IL-7: interleukin 7;
IGF-1: insulin-like growth factor 1; TREC: T cell receptor excision circles (modified from [68]).
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The levels of pro-inflammatory chemokines (MIP-1α, MIP-1β, RANTES) secreted by activated
DC, macrophages and endothelial cells and recognized by CCR5 increase in the aging thymus, just
like intrathymic lipid-laden multilocular and adipose cells (LLC), whose number is inversely related
with thymic function [76]. It was suggested that LLC derive from CCR5-expressing, perithymic and
perivascular preadipocytes, migrating into the aging thymus [77]. They produce pro-inflammatory
cytokines (LIF, Oncostatin M, IL-6, TNF-α), thus creating a pro-oxidative, cytotoxic intrathymic milieu,
which might favor thymocyte death [77]. The age-related alterations of lipid metabolism and redox
balance were studied in mouse thymus and isolated thymocytes. An evaluation of the lipidomics
profile of the whole thymus, between the ages of 4 weeks (young age) and 18 months (old age),
revealed increased amounts of triacylglycerides, cholesterol, HNE, sulfatide ceramide and ganglioside
GD1a in the aged thymus. Increased levels of cholesterol esters and HNE adducts were also found in
isolated thymocytes from elder mice, compared with younger individuals. Increased levels of TNF-α
and increased expression of CD204, a scavenger receptor of oxidized LDL, were detected in the thymic
parenchyma of older individuals, as compared to younger ones. GH reduced thymic levels of TNF-α
and HNE and increased the number of thymocytes, in accordance with several observations that
indicated growth hormone as a powerful immunomodulating agent, stimulating thymopoiesis and
limiting the number of adipocytes and fat locules in rodent and human thymus [74]. The levels of MDA
and protein carbonyls (PC), as well as of oxidized and reduced glutathione and the activities of several
antioxidant enzymes were measured in peripheral blood lymphocytes from 100 individuals, equally
subdivided into groups of ages varying from 11–20 to 51–60 years. This study evidenced distinct,
steady increases in MDA and PC levels with age, and decreasing glutathione levels and antioxidant
enzyme activities, documenting a progressive redox imbalance with aging [78]. When rats subjected
to ovariectomy, which undergo premature aging of the immune system, were subjected to dietary
supplementation with polyphenolic antioxidants (soybean and green tea polyphenols), beneficial
effects were observed on several parameters of the immune function (macrophage phagocytosis,
chemotaxis and ROS production; lymphocyte mitogenic responses; NK activity) and redox balance
(catalase and glutathione peroxidase activity, oxidized versus reduced glutathione ratio, MDA levels)
of peritoneal leukocytes [60].
5. Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) include a heterogeneous range of stem cell disorders
characterized by peripheral cytopenias and increased risk of progression to acute myeloid leukemia.
The incidence of MDS increases markedly with age. It is conservatively estimated that >10,000 new
cases of MDS occur in the United States annually [79]. In MDS, next-generation sequencing allowed the
identification of molecular mutations in nearly 90% of the patients. Consequently, molecular mutation
markers were integrated into current classification systems. The growing insights into molecular
aspects of the pathogenesis of MDS may help to predict the possible evolution towards leukemia [80].
Most MDS patients have anemia and many develop transfusion dependence and iron overload
(IOL). IOL is considered a negative independent prognostic factor, associated with a higher risk of
leukemic transformation and shorter survival [81]. Serologic and molecular markers of oxidative stress
have been evidenced in many patients with MDS [82], with the concentration of the LPO product MDA
being significantly increased in patients with MDS and IOL, compared with IOL-exempt patients and
control subjects. Moreover, both plasma nitrite and MDA concentrations were positively correlated
with the ferritin levels, suggesting a relationship between IOL and the increased production of ROS
in MDS [83]. In regard, it has to be noticed that the impact of iron on the redox balance of cells and
body fluids is strictly dependent on transferrin saturation (TSAT). In the presence of normal TSAT,
the M1 polarization of macrophages is decreased and the production of pro-inflammatory cytokines,
ROS and LPO products are inhibited [84]. Conversely, patients with IOL and high TSAT show higher
O2% saturation levels than patients at the time of diagnosis and normal controls. Antioxidant systems,
with the exception of SOD, exhibit significant activity changes in IOL patients, compared with controls.
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Moreover, iron chelation treatment with deferoxamine has also been shown to reduce cytopenia in
patients with MDS. In a study of 11 patients with MDS who were receiving deferoxamine for up to
60 months, increases in platelet and neutrophil counts were observed in 64% and 78% of patients,
respectively [85]. Furthermore, mitochondrial dysfunction has been detected only in IOL cases, but not
in control subjects [86]. High-level ROS production in MDS can be responsible for genotoxic damage
to nuclear and mitochondrial DNA, resulting in genomic instability, which contributes to disease
progression and leukemia onset [87,88].
Even though the role of ROS in MDS is well established, the role played by LPO products in
the disease and its progression has not been completely assessed. It was suggested that the loss of
ALDHs, which are mainly responsible for the metabolism of reactive aldehydes, might lead to the
alteration of various cell processes, which may foster MDS progression to leukemic transformation [89].
Recent data indicate that ALDH1A1-defective cell lines, as well as primary leukemic cells, are sensitive
to the treatment with drugs that directly or indirectly generate toxic ALDH substrates, including HNE.
On the contrary, normal HSCs are relatively resistant to these compounds, suggesting that LPO-derived
aldehydes could selectively kill ALDH1A1-defective leukemic cells [90]. According to these observations,
in human lymphoid leukemic CDM-NKR cells, high concentrations of HNE caused significant cytotoxic
effects on DNA synthesis and mitochondrial activity, whereas no significant toxicity of HNE was
detected in normal hematopoietic precursor cells [91]. In addition, murine erythroleukemia (MEL)
cells from HNE-treated mice exhibit a higher degree of differentiation, in comparison with dimethyl
sulfoxide-treated MEL cells. These findings indicate that HNE, at concentrations physiologically
detected in many normal tissues and in plasma, induces MEL cell differentiation, by modulating the
expression of specific genes [92].
However, the role of HNE and other reactive aldehydes in the development of leukemia is
controversial. The ALDH1A1 and ALDH3A1 isoforms are important for the metabolism of reactive
aldehydes and ROS, and are expressed at high levels in HSCs. Indeed, the loss of these two isoforms
resulted in a variety of effects on HSC biology, such as increased DNA damage and increased rates
of leukemic transformation [93]. On the other hand, ALDH activity in human leukemic cells also
mediates resistance to a number of drugs [94], and high levels of ALDH activity are predictors of
poor therapeutic outcomes [95]. These conclusions are supported by the identification, by the in silico
screening of the Gene Expression Omnibus database, using the PTL gene signature as a template,
of 2 new agents, celastrol and HNE, which were able to eradicate acute myeloid leukemia (AML) at
the bulk, progenitor, and stem cell level [96].
Serologic and molecular markers of oxidative stress in patients with MDS include increased
concentrations of the LPO product MDA and the presence of oxidized bases in CD34+ cells. Potential
mechanisms of oxidative stress include mitochondrial dysfunction via IOL and mitochondrial DNA
mutation, systemic inflammation, and bone marrow stromal defects [82]. MDA levels in plasma
correlated moderately with serum ferritin and free iron levels and were significantly higher in MDS
patients with iron overload, when compared to healthy blood donors, once more emphasizing the role
of oxidative stress in the development of MDS [97]. Moreover, a cytoprotective effect was reported
of erythropoietin on the plasma membrane of erythroid cells in MDS, which was closely reminiscent
of effects detected in certain conditions of impaired glucose metabolism, which were associated with
increased LPO-dependent cell stress in the elderly [98]. The selective cytotoxic activities exhibited by
LPO products towards transformed hematopoietic cells might be partly responsible for the effectiveness
of hypomethylating drugs, widely employed in the chemotherapy of AML and MDS. In fact, the use
of these chemotherapeutic agents is associated with the generation of enormous amounts of ROS.
Antioxidant supplementation in these patients must be approached with caution, because of the high
probability that it might result in significant reductions of the therapeutic efficacy of hypomethylating
drugs, whose cytotoxic effect is probably mediated by plasma MDA concentrations, which increase
significantly during the 14-day post-chemotherapy period [99].
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In conclusion, it appears that the overall effects of LPO products within the context of MDS
are strictly dependent on their concentrations, the degree of inflammation and the disease phase.
Physiological HNE and MDA concentrations in an early phase of MDS, with low-grade inflammation
and normal iron concentrations, seem to favor blast apoptosis and normal hematopoietic cell
differentiation in bone marrow niches, whereas high HNE and MDA concentrations in later phases
of MDS, with high-grade inflammation and higher than normal iron levels, might favor normal cell
death and awry maturation of bone marrow cells [99].
6. Conclusions
From the overall body of evidence presented, the pathogenic involvement of oxidative
stress and lipid peroxidation appears to be firmly grounded in all of the senile pathological
and dysfunctional conditions examined in this review. In turn, increases in the production of
ROS and reactive aldehydes from lipid peroxidation concur to induce apoptosis, which has been
observed during aging in osteoblasts, muscle cells, thymocytes and hematopoietic cells. The use of
antioxidants as an adjuvant therapy to counteract ROS increases in these disorders gave interesting
results [26,87,100,101]. However, the efficacy of antioxidants in reducing the concentrations of
aldehydes and/or protein-aldehyde adducts in blood or in tissues has not yet been measured. It is
our conception that osteoporosis/osteopenia, sarcopenia, immunosenescence and myelodysplastic
syndromes may all represent concurring expressions of the age-related decay of molecular turnover
and repair capabilities in post-mitotic cells, altogether expressing themselves as the progressive
multiorgan/multisystem failure of senescence. A few systematic redox proteomic approaches,
pinpointing the modifications of distinct cell proteins with LPO products generated in the course of
oxidative stress, have been conducted to date, mostly in the skeletal muscle of rodents. It is warranted
that studies of this kind be extended to the other organ systems undergoing age-associated decay,
and be complemented by functional studies as well. We anticipate that continuing investigation in this
field may pave the way, in the end, to targeted therapeutic strategies aiming to alleviate the burden of
morbidity and mortality associated with these disturbances.
Author Contributions: G.B. and F.G. wrote the paper, S.P., M.D., C.D., A.A, G.P.C., G.G., M.A.C. and M.G. were
involved in the previous work on these topics in our group and/or substantively revised it.
Funding: This work was supported by the University of Turin and the Department of Clinical and Biological
Sciences (Local Funds ex-60%).
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
ALDH aldehyde dehydrogenase
AML acute myeloid leukemia
apoB apolipoprotein B
CMV cytomegalovirus
DNPH dinitrophenylhydrazine
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